间接治疗比较表明，在慢性淋巴细胞白血病患者的一线治疗中，IMBRUVICA®（依鲁替尼）联合维奈托克相比阿卡替尼联合维奈托克具有显著的疗效优势

Significant efficacy benefit of IMBRUVICA® (ibrutinib) plus venetoclax versus acalabrutinib plus venetoclax in frontline treatment of patients with chronic lymphocytic leukaemia suggested by indirect treatment comparison

强生 等信源发布 2025-06-12 05:57



可切换为仅中文







微信扫码分享